The pharmacological activity assessment of novel immunomodulatory drugs in early-stage drug development is challenging as healthy volunteers do not express relevant immune biomarkers. Alternatively, the system can be challenged with keyhole limpet hemocyanin (KLH), a suitable antigen for studying adaptive responses. This report systemically reviews KLH challenge clinical studies focusing on cha...